A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China (opens in new tab)

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China CNBCLung Cancer Patients on Drug From China’s Akeso Lived Longer Bloomberg.comASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Fierce PharmaAkeso and Summit’s ivonescimab extends survival in squamous cell lung cancer statnews.comSummit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers BioSpace